Uncategorized
FDA warns anti-seizure drug may cause skin discoloration, vision loss
The FDA has announced that there are potential vision loss risks because of pigment changes in the retina and possible skin discoloration for patients treated with the anti-seizure drug Potiga, according to reviews of additional safety data.By following the current recommendations on Potiga (ezogabine, GlaxoSmithKline), the risks can be adequately managed, the FDA announced in a press release. The FDA has mandated GlaxoSmithKline to conduct a long-term observational study of ezogabine to examine possible long-term consequences of the pigment changes, the release stated.